Connect with us

Technology

Elsevier announces expansion to their flagship clinical decision support solution, ClinicalKey AI

Published

2 years ago

on

New functionality and partnerships make it easier for clinicians to access crucial information at the point of care and log learning credits.

NEW YORK, March 3, 2025 /PRNewswire/ — Elsevier, a global leader in health information and data analytics, has announced further enhancements to ClinicalKey AI, the company’s leading generative AI-powered clinical decision support solution. The new functionality and integrations with strategic partners aim to transform the way healthcare providers access and utilize actionable insights, enhancing patient care and efficiency directly within the clinician’s workflow.

Seamless workflows are crucial for doctors as they enable them to focus more on patient care, reduce time-consuming administrative tasks, and access relevant information efficiently. To serve the needs of busy clinicians, ClinicalKey AI is launching new workflow integrations in the electronic health record (EHR) with Epic[1] and into the health information technology (HIT) space with iPrescribe by DrFirst, along with a new mobile app available for Apple and Android users.

The new EHR integration will streamline workflows, enabling clinicians to switch between Epic’s EHR and ClinicalKey AI without needing to navigate away from patient records. ClinicalKey AI can be found in Connection Hub on Epic Showroom, providing a cohesive experience for clinicians, simplifying the process for accessing essential information at the point of care. A new ClinicalKey AI mobile app will further boost access, enhancing clinicians’ ability to access critical information on the go.

Dr. Barry Wendt, Chief Medical Information Officer at St. Elizabeth Healthcare, a development partner on the Epic EHR integration, said: “Clinicians are working under increasing pressure, treating multiple patients with complex cases, and simplifying access to vital information is paramount. With ClinicalKey AI’s seamless integration with the Epic EHR system, clinicians can easily move between the patient’s EHR and the latest evidence-based content, helping them save valuable time when they’re treating patients at the point of care.”

The collaboration with DrFirst, which has solutions used by more than 450,000 prescribers, adds the power of ClinicalKey AI decision support to the company’s iPrescribe by DrFirst HIT platform. “Each day, prescribers make the most of every moment to take care of their patients, even while traveling between their homes, various offices, and other facilities,” said Colin Banas, M.D., M.H.A., Chief Medical Officer of DrFirst. “Making this world-class, evidence-based research tool available within the iPrescribe by DrFirst app gives healthcare providers across all practice sizes and specialties instant access to AI-powered conversational searches of clinical literature—helping them make informed prescribing decisions from anywhere.”

In addition to these new access-enhancing features, ClinicalKey AI will also enable clinicians to earn, track, and claim Continuing Medical Education (CME) and Maintenance of Certification (MOC) credits directly within the platform. Healthcare professionals will be able to earn CME credits through each clinical query and response interaction, seamlessly integrating learning into their daily workflow.

Furthermore, ClinicalKey AI will support auto-submission of MOC credits to American Boards of eight different specialties (internal medicine, pediatrics, anesthesiology, surgery, pathology, otolaryngology, orthopedic surgery and thoracic surgery). This will make ClinicalKey AI the first AI solution of this kind with this capability.

Omry Bigger, President of Clinical Solutions at Elsevier said: “Healthcare professionals continue to face growing pressures on their time while operating in a fast-moving work environment. Since launching ClinicalKey AI in 2024 as the first Gen-AI solution of its kind, we have continued to expand functionality to support clinicians by streamlining processes, improving access and boosting CME, helping them respond to the challenges they face every day.”

ClinicalKey AI is available in over 50 countries and provides answers from a content set that is specifically curated for point of care questions. It enables access to Elsevier titles such as The Lancet, Goldman-Cecil, as well as non-Elsevier titles and a host of other evidence-based sources. Today’s announcement builds on the expanded partnership with the American College of Cardiology (ACC) announced earlier this year, which made the ACC’s Clinical Practice Guidelines and Expert Consensus Decision Pathways on a range of cardiology topics available on ClinicalKey AI.

You can learn more about ClinicalKey AI on our website, and also at the upcoming 2025 HIMSS Conference in Las Vegas. Join the Elsevier team at booth 3616 and AI Pavilion Kiosk 121-14 to find out more about ClinicalKey AI. You can also hear from Elsevier spokespeople Dr. Amber Featherstone-Uwague (3:10 p.m., March 4) and Dr. Paul “PJ” Helmuth (2 p.m., March 5) at speaking sessions in the AI Pavillion.

About Elsevier
As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. 

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com. 

About iPrescribe by DrFirst
iPrescribe by DrFirst is the industry-leading e-prescribing solution, trusted by healthcare providers throughout the U.S. It enables safe and efficient prescribing of controlled and non-controlled substances anytime, anywhere. Built for mobility and designed to adapt to any workflow, iPrescribe ensures seamless, compliant prescribing across all practice settings. Whether used as a standalone mobile solution or integrated with an EHR, iPrescribe delivers flexibility for in-office and after-hours needs. DrFirst solutions help 100 million patients a year and are used by more than 450,000 prescribers, 71,000 pharmacies, 270 EHRs and health information systems, and over 2,000 hospitals in the U.S. To learn more, visit iPrescribe.com and DrFirst.com.

Logo – https://mma.prnewswire.com/media/2628519/5194789/Elsevier_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/elsevier-announces-expansion-to-their-flagship-clinical-decision-support-solution-clinicalkey-ai-302390584.html

Related Topics:
Continue Reading

Technology

BCE reports results of Series S and T preferred share conversions

Published

2 minutes ago

on

October 19, 2026

By

MONTRÉAL, Oct. 19, 2026 /CNW/ — BCE Inc. (TSX: BCE) (NYSE: BCE) today announced that 400 of its 4,798,333 fixed-rate Cumulative Redeemable First Preferred Shares, Series T (“Series T Preferred Shares”) have been tendered for conversion on November 2, 2026, on a one-for-one basis, into floating-rate Cumulative Redeemable First Preferred Shares, Series S (“Series S Preferred Shares”). In addition, 676,765 of its 1,866,877 Series S Preferred Shares have been tendered for conversion on November 2, 2026, on a one-for-one basis, into Series T Preferred Shares. Consequently, on November 2, 2026, BCE will have 5,474,698 Series T Preferred Shares and 1,190,512 Series S Preferred Shares issued and outstanding. The Series T Preferred Shares and the Series S Preferred Shares will continue to be listed on the Toronto Stock Exchange under the symbols BCE.PR.T and BCE.PR.S, respectively.

The Series T Preferred Shares will pay on a quarterly basis, for the five-year period beginning on November 2, 2026, as and when declared by the Board of Directors of BCE, a fixed cash dividend based on an annual fixed dividend rate of 5.523%.

The Series S Preferred Shares will continue to pay a monthly floating adjustable cash dividend for the five-year period beginning on November 2, 2026, as and when declared by the Board of Directors of BCE. The monthly floating adjustable dividend for any particular month will continue to be calculated based on the prime rate for such month and using the Designated Percentage for such month representing the sum of an adjustment factor (based on the market price of the Series S Preferred Shares in the preceding month) and the Designated Percentage for the preceding month.

About BCE
BCE is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.

1 Based on total revenue and total combined customer connections.

Media inquiries:
Ellen Murphy
media@bell.ca

Investor inquiries:
Krishna Somers
krishna.somers@bell.ca

View original content:https://www.prnewswire.com/news-releases/bce-reports-results-of-series-s-and-t-preferred-share-conversions-302913268.html

SOURCE BCE Inc.

Continue Reading

Technology

3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development

Published

1 hour ago

on

October 19, 2026

By

ST. PAUL, Minn., Oct. 19, 2026 /PRNewswire/ — 3M (NYSE: MMM) today announced a collaboration with Genius Electronic Optical Co., Ltd. (GSEO, Taiwan: 3406), an optical technology company, to advance technology development and manufacturing for 3M’s Expanded Beam Optical (EBO) solutions. In support of these efforts, 3M expects to make a strategic investment to acquire approximately 4.7% of GSEO’s common shares as part of the company’s private placement of newly issued shares, subject to customary closing conditions.

The collaboration brings together 3M’s EBO technology leadership, optical interconnect expertise, materials science, manufacturing scale and customer relationships with GSEO’s precision optics manufacturing capabilities and production scale. Together, the companies aim to support EBO commercialization and long-term capacity expansion to meet growing demand from hyperscale data centers and other advanced connectivity applications.

“3M is investing in capabilities and partnerships that can accelerate innovation for our customers,” said William Brown, 3M Chairman and CEO. “By selecting GSEO as a manufacturing partner and investing in the company, we are strengthening the path to scale next-generation optical connectivity solutions for high-performance data center infrastructure.”

GSEO’s existing precision optics manufacturing capabilities and technical development experience are expected to support manufacturing readiness for 3M’s EBO ferrules, co-packaged optics solutions and related optical interconnect applications. The collaboration is part of 3M’s broader EBO ecosystem strategy, which includes continued work with customers and partners across the optical interconnect market.

“GSEO is pleased to expand its relationship with 3M as we work together to advance optical interconnect solutions for next-generation data center infrastructure,” said Micro Kuo, GSEO CEO and President. “This collaboration brings together complementary technology and manufacturing strengths to support continued innovation and help meet the performance demands of high-growth connectivity markets.”

3M expects the strategic investment to close in the fourth quarter of 2026, subject to customary closing conditions.

Forward-Looking Statements
Certain statements in this release are considered “forward-looking statements” under the federal securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of those laws. Forward-looking statements may appear throughout this release and are typically identified by the words “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “forecast,” “future,” “goal,” “guidance,” “impact,” “initial,” “intend,” “likely,” “may,” “outlook,” “plan,” “possible,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and other words that are similar to, or have the opposite meanings of, those words. Forward-looking statements speak only as of the date they are made, 3M assumes no duty to update those statements, and readers are cautioned not to place undue reliance on any of those statements. Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of 3M’s Form 10-K for the year ended December 31, 2025.

About 3M
3M (NYSE: MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3M.com/news.

Contacts
3M
Investor Contact:
Diane Farrow, 612-202-2449
Media Contact:
3MNews@mmm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-announces-collaboration-with-gseo-to-advance-expanded-beam-optical-manufacturing-and-development-302913170.html

SOURCE 3M Company

Continue Reading

Technology

Scott Vicknair Personal Injury Lawyers Announces Second Annual Operation Fur-Ever Home Pet Adoption Event at Lafreniere Park

Published

1 hour ago

on

October 19, 2026

By

NEW ORLEANS, Oct. 19, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is excited to announce the return of its second annual Operation Fur-Ever Home, a free community pet adoption event taking place on Saturday, November 14, 2026, from 9:00 a.m. to 11:00 a.m. at Lafreniere Park in Metairie, Louisiana.

The free, family-friendly event will give attendees the opportunity to meet adoptable pets from local animal shelters, learn about responsible pet ownership, and potentially welcome a new furry companion into their homes. Those who preregister for the event will also be entered for a chance to win a Soundcore speaker and a free pet adoption.

“Last year’s event was everything we hoped it would be, and we are incredibly excited to bring Operation Fur-Ever Home back for a second year,” said David Vicknair, founding partner of Scott Vicknair Personal Injury Lawyers. “There is something special about watching a family meet a pet that could become part of their lives for years to come. We wanted to create another opportunity to make those connections while supporting the organizations that work tirelessly to care for animals in our community.”

Building on the success of the first event, this year’s event continues the firm’s commitment to supporting local animal shelters and creating meaningful opportunities for families throughout Southeast Louisiana.

“Giving back to our community has always been an important part of who we are as a firm,” said Vicknair. “Whether we are helping students prepare for school, recognizing deserving teachers, or supporting local animal shelters, our goal is to make a positive difference in the communities we serve.”

Operation Fur-Ever Home is free and open to the public. Families, animal lovers, and anyone interested in adopting a pet are encouraged to attend and preregister.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal strategies tailored to each client’s specific case and needs.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-second-annual-operation-fur-ever-home-pet-adoption-event-at-lafreniere-park-302913183.html

SOURCE Scott Vicknair Personal Injury Lawyers

Continue Reading

Trending